NGeneBio Co., Ltd. has completed an IPO in the amount of KRW 34.216 billion.
December 04, 2020 at 10:30 am IST
Share
NGeneBio Co., Ltd. has completed an IPO in the amount of KRW 34.216 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,444,000
PriceRange: KRW 14000
Discount Per Security: KRW 490
Transaction Features: Sponsor Backed Offering
NGeneBio Co Ltd is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.
NGENEBIO CO., LTD. 
